Stock 688179 SHANGHAI ALADDIN BIOCHEMICAL TECHNOLOGY CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai Aladdin Biochemical Technology Co.,Ltd.

Equities

688179

CNE100005XD0

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
11.09 CNY -0.09% Intraday chart for Shanghai Aladdin Biochemical Technology Co.,Ltd. +0.45% -18.97%
Apr. 29 Shanghai Aladdin Biochemical Technology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 19 Shanghai Aladdin Biochemical Technology Co.,Ltd. agreed to acquire 51% stake in Shanghai Yuanye Biotechnology Co., Ltd. for CNY 180 million from Cui Yuanyuan and Tan Xiaoyong. CI

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's profit outlook over the next few years is a strong asset.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 12.42 for the current year.

Weaknesses

  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI ALADDIN BIOCHEMICAL TECHNOLOGY CO.,LTD. Stock Shanghai Aladdin Biochemical Technology Co.,Ltd.
-18.97% 425M -
MODERNA, INC. Stock Moderna, Inc.
+43.36% 58.06B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 40.53B
B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.99B
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.7B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.56B
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.98B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.17B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.92B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. 688179 Stock
  4. Ratings Shanghai Aladdin Biochemical Technology Co.,Ltd.